ARLINGTON, Texas, June 7, 2022 /PRNewswire/ — With heart disease being the leading cause of death in the United States, Texas Health Resources is addressing the problem with quality, science-based guidelines for treating heart attack patients. This focus on quality care helped eight Texas Health facilities earn this year’s American College of Cardiology’s […]
Coronary/Structural Heart
Acarix signs additional commercial agreement in US and receives rapid orders in both Mississippi and Tennessee
Acarix today announces an additional commercial partnership in the US covering the states of Tennessee, Kentucky, Mississippi, and Alabama. The new partnership with Ancillary Care Services LLC has led to rapid orders and use of the CADScor® System by regional and rural clinics to enable accessible, rapid and cost-effective rule out of coronary artery disease. The US states of Tennessee, Kentucky, Mississippi, and Alabama have among the highest prevalence rates for heart disease in […]
Family Heart Foundation’s Analysis of Large U.S. Healthcare Dataset Shows Measurement of Lipoprotein(a) Is Rare
Data Highlighted in Poster Presentation at the National Lipid Association Scientific Sessions SCOTTSDALE, Ariz.–(BUSINESS WIRE)–The Family Heart Foundation, a leading research and advocacy organization, completed an analysis of its large U.S. Family Heart DatabaseTM demonstrating that lipoprotein(a) – also referred to as Lp(a) — is rarely assessed, despite it being a common, independent […]
LumiraDx Expands its Cardiovascular Testing Portfolio with CE Marking of its NT-proBNP Test and new Exclusion Claim for its D-Dimer Test
The LumiraDx NT-proBNP and the LumiraDx D-Dimer tests are currently the only quantitative direct fingerstick assays produced for each test. Run on the highly portable LumiraDx Platform, they are designed for near-patient testing with connected results in 12 minutes and 6 minutes, respectively The LumiraDx NT-proBNP test is a rapid microfluidic […]
Renovacor Announces Data from Pilot Pig Study Showing Successful Cardiac Transduction with REN-001 Delivered Via Low-Dose Retrograde Coronary Sinus Infusion Published in Journal of the American College of Cardiology: Basic to Translational Research
REN-001 delivered locally via low-dose retrograde coronary sinus infusion demonstrated robust, diffuse cardiomyocyte transduction in a large animal heart CAMBRIDGE, Mass.–(BUSINESS WIRE)–Renovacor, Inc. (NYSE: RCOR), a biotechnology company focused on delivering innovative precision therapies to improve the lives of patients and families battling genetically-driven cardiovascular and mechanistically-related diseases, today announced […]
GE Healthcare, Medtronic Partnership Accelerates Global Access to Personalized Care by Delivering Advanced Patient Monitoring Solutions on the CARESCAPE Platform
GE Healthcare, Medtronic receive FDA 510(k) clearance and CE Mark approval on the integration of advanced INVOS™ regional oximetry and Microstream™ capnography technologies on the CARESCAPE precision monitoring platform Helping providers improve patient outcomes and safety, Microstream™ capnography (CO2) technology captures evolving respiratory compromise while INVOS™ regional oximetry (rSO2) technology […]
Chiesi USA Announces First Analysis from the CAMEO Registry Assessing KENGREAL® (cangrelor) Use and Transition to Oral P2Y12 Inhibitors in Routine Clinical Practice
The CAMEO registry, an ongoing study to provide real-world data on KENGREAL® (cangrelor), has published interim results in the Journal of the American Heart Association. This analysis from CAMEO is the first analysis of its kind to describe acute medication administration in a percutaneous coronary intervention (PCI) setting with transition […]
Recardio and FDA Reach Agreement on Pivotal Phase 3 Trial Design
Recardio Inc., a late stage clinical-stage life science company developing regenerative therapies for cardiovascular diseases, announced that the FDA concurs with Recardio’s pivotal Heal-MI Phase 3 trial design with Dutogliptin in Acute Myocardial Infarction. SAN FRANCISCO, June 01, 2022 (GLOBE NEWSWIRE) — Recardio’s Phase 2 trial results demonstrated the excellent […]
CinCor Pharma Doses First Patient in Phase 2 FigHTN-CKD Trial Evaluating the Selective Aldosterone Synthase Inhibitor Baxdrostat (CIN-107) in Patients with Uncontrolled Hypertension and Chronic Kidney Disease
figHTN-CKD is CinCor’s fourth ongoing Phase 2 clinical trial evaluating baxdrostat (CIN-107) Initial topline data for figHTN-CKD expected in 2H 2023 WALTHAM, Mass., June 01, 2022 (GLOBE NEWSWIRE) — CinCor Pharma, Inc. (“CinCor”) announced today that the first patient has been dosed in the Phase 2 figHTN-CKD trial evaluating baxdrostat […]
DynamX Bioadaptor Restores Rotational Motion and Vessel Stress Reduction in New Study
Paper Published in Cardiovascular Revascularization Medicine Shows Innovative Coronary Artery Implant is Capable of Moving with Vessel, Unlike Conventional Stents MILPITAS, Calif.–(BUSINESS WIRE)–Elixir Medical, a developer of innovative, drug-eluting cardiovascular devices, today announced print publication of a study in the latest issue of Cardiovascular Revascularization Medicine that showed that the DynamX™ […]



